Skip to Main Content
Yale-BI Biomedical Data Science Fellowship
Yale Home

INFORMATION FOR

    Zenta Walther, MD, PhD

    Associate Professor of Pathology
    DownloadHi-Res Photo

    Are You a Patient?

    View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

    View Doctor Profile

    Additional Titles

    Director, Molecular Genetic Pathology Fellowship Program

    About

    Titles

    Associate Professor of Pathology

    Director, Molecular Genetic Pathology Fellowship Program

    Biography

    Dr. Walther is a physician-scientist with clinical expertise in gastrointestinal and liver pathology, the molecular diagnostics of surgical pathology specimens, and molecular oncology of solid tumors. Dr. Walther served as Clinical Director of the YNHH Tumor Profiling Laboratory for 12 years through the end of 2023, where she focused on molecular and genomic analyses of solid tumor specimens, to enable the identification of therapeutic targets within individual patients' cancers, and thus to promote precision medicine in oncology. She remains a key faculty member in the TPL and serves as Director of the Molecular Genetic Pathology Fellowship.

    Last Updated on January 08, 2024.

    Appointments

    Other Departments & Organizations

    Education & Training

    Fellow
    Yale University School of Medicine (2011)
    Fellow
    Yale University School of Medicine (2001)
    Resident
    Yale University School of Medicine (1997)
    MD
    Cornell University (1995)
    PhD
    Rockefeller University (1994)
    BS
    Yale University (1986)

    Research

    Research at a Glance

    Yale Co-Authors

    Frequent collaborators of Zenta Walther's published research.

    Publications

    2025

    • A Concordance Study Among 26 NGS Laboratories Participating in the National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) Clinical Trial
      Zane L, Yee L, Chang T, Sklar J, Yang G, Di Wen J, Li P, Harrington R, Sims D, Harper K, Trent J, LoBello J, Szelinger S, Benson K, Zeng J, Poorman K, Xu D, Frampton G, Pavlick D, Miller V, Tandon B, Swat W, Weiss L, Funari V, Conroy J, Prescott J, Chandra P, Ma C, Champion K, Baschkopf G, Fesko Y, Freitas T, Tomlins S, Hovelson D, White K, Sorrells S, Tell R, Beaubier N, King D, Li L, Kelly K, Uvalic J, Meyers B, Kolhe R, Lindeman N, Baltay M, Sholl L, Lopategui J, Vail E, Zhang W, Telatar M, Afkhami M, Hsiao S, Mansukhani M, Adams E, Jiang L, Aldape K, Raffeld M, Xi L, Stehr H, Segal J, Aisner D, Davies K, Brown N, Livingston R, Konnick E, Song W, Solomon J, Walther Z, McShane L, Harris L, Chen A, Tsongalis G, Hamilton S, Flaherty K, O’Dwyer P, Conley B, Patton D, Iafrate A, Williams P, Tricoli J, Karlovich C. A Concordance Study Among 26 NGS Laboratories Participating in the National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) Clinical Trial. Clinical Cancer Research 2025, 31: 3512-3525. PMID: 40465838, PMCID: PMC12284871, DOI: 10.1158/1078-0432.ccr-24-2188.
      Peer-Reviewed Original Research
    • Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
      Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, Le J, Montesion M, Palmer R, Jahchan N, Juan J, Min C, Yu Y, Pan X, Arbour K, Vokes N, Schmidt S, Molkentine D, Owen D, Memmott R, Patil P, Marmarelis M, Awad M, Murray J, Hellyer J, Gainor J, Dimou A, Bestvina C, Shu C, Riess J, Blakely C, Pecot C, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian M, Sacher A, Lau S, Saltos A, Rotow J, Johnson R, Liu C, Stewart T, Goldberg S, Killam J, Walther Z, Schalper K, Davies K, Woodcock M, Anagnostou V, Marrone K, Forde P, Ricciuti B, Venkatraman D, Van Allen E, Cummings A, Goldman J, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok J, Segal J, Ritterhouse L, Neal J, Lacroix L, Elamin Y, Negrao M, Le X, Lam V, Lewis W, Kemp H, Carter B, Roth J, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula A, Parra Cuentas E, Behrens C, Wistuba I, Zhang J, Blumenschein G, Gay C, Byers L, Gibbons D, Tsao A, Lee J, Bivona T, Camidge D, Gray J, Leighl N, Levy B, Brahmer J, Garassino M, Gandara D, Garon E, Rizvi N, Scagliotti G, Wolf J, Planchard D, Besse B, Herbst R, Wakelee H, Pennell N, Shaw A, Jänne P, Carbone D, Hellmann M, Rudin C, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson M, Wong K, Huang A, Winslow M, Rosen M, Winters I, Papadimitrakopoulou V, Cascone T, Jewsbury P, Heymach J. Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 2025, 639: e19-e19. PMID: 40016449, PMCID: PMC11903295, DOI: 10.1038/s41586-025-08767-9.
      Commentaries, Editorials and Letters

    2024

    • CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
      Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Galan-Cobo A, Le J, Montesion M, Palmer R, Jahchan N, Juan J, Min C, Yu Y, Pan X, Arbour K, Vokes N, Schmidt S, Molkentine D, Owen D, Memmott R, Patil P, Marmarelis M, Awad M, Murray J, Hellyer J, Gainor J, Dimou A, Bestvina C, Shu C, Riess J, Blakely C, Pecot C, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian M, Sacher A, Lau S, Saltos A, Rotow J, Johnson R, Liu C, Stewart T, Goldberg S, Killam J, Walther Z, Schalper K, Davies K, Woodcock M, Anagnostou V, Marrone K, Forde P, Ricciuti B, Venkatraman D, Van Allen E, Cummings A, Goldman J, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok J, Segal J, Ritterhouse L, Neal J, Lacroix L, Elamin Y, Negrao M, Le X, Lam V, Lewis W, Kemp H, Carter B, Roth J, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula A, Parra Cuentas E, Behrens C, Wistuba I, Zhang J, Blumenschein G, Gay C, Byers L, Gibbons D, Tsao A, Lee J, Bivona T, Camidge D, Gray J, Leighl N, Levy B, Brahmer J, Garassino M, Gandara D, Garon E, Rizvi N, Scagliotti G, Wolf J, Planchard D, Besse B, Herbst R, Wakelee H, Pennell N, Shaw A, Jänne P, Carbone D, Hellmann M, Rudin C, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson M, Wong K, Huang A, Winslow M, Rosen M, Winters I, Papadimitrakopoulou V, Cascone T, Jewsbury P, Heymach J. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 2024, 635: 462-471. PMID: 39385035, PMCID: PMC11560846, DOI: 10.1038/s41586-024-07943-7.
      Peer-Reviewed Original Research
    • ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
      Hu B, Wiesehöfer M, de Miguel F, Liu Z, Chan L, Choi J, Melnick M, Estape A, Walther Z, Zhao D, Lopez-Giraldez F, Wurtz A, Cai G, Fan R, Gettinger S, Xiao A, Yan Q, Homer R, Nguyen D, Politi K. ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts. Cancer Research 2024, 84: 1303-1319. PMID: 38359163, PMCID: PMC11142404, DOI: 10.1158/0008-5472.can-23-0438.
      Peer-Reviewed Original Research

    2023

    See All Publications

    Clinical Trials

    Current Trials

    Clinical Care

    Overview

    Zenta Walther, MD, PhD, is the clinical director of the Yale New Haven Hospital Tumor Profiling Laboratory, and a pathologist who specializes in using molecular diagnostic techniques, especially next-generation sequencing, to analyze solid tumor tissues from patients. In particular, Dr. Walther looks for mutations within tumors that could be targeted with specific cancer drugs.

    “I try to make personalized medicine possible for cancer patients,” Dr. Walther says. “And targeted therapies can often have fewer toxic side effects than conventional chemotherapy. I’m always eager to help patients find and enroll in available clinical trials.”

    As an associate professor of pathology at Yale School of Medicine, Dr. Walther participates in translational research in addition to her clinical work. “By studying the genetic alterations in tumors before and after targeted therapy, we hope to gain new understanding that will lead to better treatment regimens and, ultimately, better outcomes for cancer patients.”

    Clinical Specialties

    Anatomic Pathology; Molecular & Genomic Pathology

    Fact Sheets

    Board Certifications

    • Anatomic Pathology

      Certification Organization
      AB of Pathology
      Original Certification Date
      2001

    Are You a Patient?

    View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

    View Doctor Profile

    Get In Touch

    Contacts

    Email
    Academic Office Number
    Office Fax Number

    Administrative Support

    Locations

    • Patient Care Locations

      Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

      See Patient Care Locations